Clinical trials: Hematological Disease
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: Ruxolitinib
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation
- Trial name
- NCT03286530
- Testing
- Ruxolitinib
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Chronic Pain, Depression Disorders
Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study
What is the purpose of this study? The use of medicinal cannabis has grown significantly in Brazil. However, because many patients use these products through "compassionate use" (when traditional treatments haven't worked), there…
- Conditions
- Chronic Pain, Depression Disorders, Anxiety Disorders, Quality of Life
- Trial name
- CANAREAL (NCT07362407)
- Testing
- Participants are followed while using cannabis-based products (such as CBD or THC oils, extracts, or isolates) as prescribed by their own physicians for therapeutic purposes.
- Where
- Brazil
- Volunteers
- 384 people
- Sponsor
- Santa Catarina Federal University
Pseudoxanthoma Elasticum
Oral Pyrophosphate Absorption in PXE Disease
Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi).
- Trial name
- NCT04441671
- Testing
- Disodium Pyrophosphate
- Sponsor
- Tampere University Hospital
Hepatitis C, Hemophilia
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection.
- Trial name
- NCT00707772
- Testing
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
- Where
- Iran
- Volunteers
- 400 people
- Sponsor
- Baqiyatallah Medical Sciences University
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
- Trial name
- NCT02848001
- Testing
- CC-90009
- Where
- 20 sites in United States, Canada and 4 more
- Volunteers
- 101 people
- Sponsor
- Celgene
Venous Insufficiency (Chronic)(Peripheral), Venous Reflux
Adrenaline Reduces Ecchymoses and Hematomas and Improves Quality of Life After Classic Saphenous Vein Stripping
Aim of the present study is to investigate the efficiency of adrenaline (epinephrine) used locally in reducing and avoiding post-operative formation of subcutaneous ecchymoses and hematomas, in comparison with traditional…
- Conditions
- Venous Insufficiency (Chronic)(Peripheral), Venous Reflux, Venous Insufficiency of Leg, Venous Stasis
- Trial name
- ARESQOLSAVES (NCT04758728)
- Testing
- Great saphenous vein stripping and varicectomies, Epinephrine Topical, normal saline
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Junior Doctors Network-Hellas
COVID-19
Thromboelastographic Methods in Deciding Therapy on Moderate to Severe COVID-19 Patients
This study is a prospective observational study that compares the anticoagulant therapy decision time among moderate and severe COVID-19 patients whose coagulation profiles were tested with thromboelastography (TEG) to those with…
- Trial name
- NCT05343728
- Testing
- Thromboelastography, Standard coagulation profile laboratory examination
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Universitas Indonesia
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT00384228
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukaemia
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.
- Trial name
- NCT05286528
- Testing
- Bosutinib, Imatinib, Nilotinib
- Where
- Hungary
- Volunteers
- 1,484 people
- Sponsor
- Pfizer
Smoldering Multiple Myeloma
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: Lenalidomide Citarinostat (CC-96241) PVX-410
- Trial name
- NCT02886065
- Testing
- Hiltonol, Citarinostat, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
The main purpose of this study is to evaluate the effects of repeat dosing of ibrutinib on the single-dose pharmacokinetics (PK) of oral contraceptives (OC - ethinylestradiol [EE] and levonorgestrel [LN]), the cytochrome P450…
- Trial name
- NCT03301207
- Testing
- Ibrutinib, OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg, Bupropion
- Where
- 4 sites in Poland, Spain
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Fatigue, Leukemia
Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation
Physiological changes caused by hematological diseases associated with high dose chemotherapy have a negative impact on patient's functionality, making them more fragile and vulnerable after hematopoietic cell transplantation.
- Conditions
- Fatigue, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT04496011
- Testing
- Aerobic training with cycle ergometer
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Thalassemia, Sickle Cell Disease
Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
The investigators' primary objective is to study prevalences of myocardial iron overload, defined as a cardiac T2*< 20 ms, in 3 populations of multiply transfused patients, affected with thalassemia, sickle cell disease, and…
- Conditions
- Thalassemia, Sickle Cell Disease, Myelodysplasia
- Trial name
- SUFEMYO (NCT01911871)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory…
- Trial name
- NCT03476239
- Testing
- Blinatumomab, Dexamthasone
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- Amgen
Relapsed or Refractory Multiple Myeloma
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in…
- Trial name
- NCT06055075
- Testing
- Forimtamig, Carfilzomib, Daratumumab
- Where
- 8 sites in Australia, Canada and 4 more
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Disease/Condition Name Cancer-related Cognitive Dysfunction, Chronic Lymphocytic Leukemia (CLL)
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
- Conditions
- Disease/Condition Name Cancer-related Cognitive Dysfunction, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Trial name
- TKI (NCT07638007)
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Rochester NCORP Research Base
Multiple Myeloma
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
To evaluate the efficacy and safety of investigational drug Colchicine combined with conventional lenalidomide based therapy in multiple myeloma subjects who had received first-line therapy (including Chimeric antigen receptor…
- Trial name
- NCT05802992
- Testing
- Colchicine, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Chronic Granulomatous Disease
Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)
The purpose of this study is to find a dose for a twice daily regimen for posaconazole (PSZ) as prophylactic treatment in children with CGD, based on the PSZ trough level.
- Trial name
- iPOD (NCT00799071)
- Testing
- posaconazole (PSZ)
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Radboud University Medical Center
Blood Disease
QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study
Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods
- Trial name
- NCT05305534
- Testing
- QIAstat-Dx® BCID GN and GPF Plus AMR Panels
- Where
- United Kingdom
- Volunteers
- 2,142 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Multiple Myeloma
MUK Nine b: OPTIMUM Treatment Protocol
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk…
- Trial name
- MUKnineb (NCT03188172)
- Testing
- Cyclophosphamide, Bortezomib, Lenalidomide
- Where
- 21 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Leeds
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.